SCHEMBL3698108

SCHEMBL3698108

CN1CCN(C(c2ccc(F)cc2)c2cc(-c3ccc4[nH]cc(C#N)c4c3)ccc2F)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACHE P22303 1/20 0.38
▸ MPO P05164 3/20 0.37
▸ P4HB P07237 1/20 0.34
▸ SLC6A4 P31645 2/20 0.34
▸ ALK Q9UM73 1/20 0.34
▸ PSMD14 O00487 1/20 0.33
▸ HSP90AA1 P07900 1/20 0.33
▸ MMP2 P08253 1/20 0.33
▸ TDO2 P48775 1/20 0.33
▸ DGKI O75912 1/20 0.33
▸ DGKA P23743 1/20 0.33
▸ DGKZ Q13574 1/20 0.33
▸ HTR1A P08908 1/20 0.33
▸ HTR1D P28221 1/20 0.33
▸ HTR1B P28222 1/20 0.33
▸ HTR1F P30939 1/20 0.33
▸ SLC1A2 P43004 1/20 0.33
▸ KCNH2 Q12809 1/20 0.33
▸ DRD2 P14416 1/20 0.32
▸ DRD4 P21917 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27693859 1.00 ACHE (0.38) ACHEMPOP4HBSLC6A4ALK
SCHEMBL3694945 0.90 TDO2 (0.39) ACHEP4HBSLC6A4TDO2DRD2
SCHEMBL27693921 0.90 TDO2 (0.39) ACHEP4HBSLC6A4TDO2DRD2
SCHEMBL3694550 0.86 MPO (0.39) ACHEMPOP4HBSLC6A4PSMD14
SCHEMBL3696398 0.81 OPRD1 (0.35) HTR1AHTR1DHTR1BHTR1FSLC1A2
SCHEMBL3695528 0.80 CYP19A1 (0.43) ACHEP4HBSLC6A4HTR1AKCNH2
SCHEMBL3695743 0.75 TGFBR1 (0.42) P4HB
SCHEMBL3698224 0.73 KCNH2 (0.45) SLC6A4KCNH2
SCHEMBL3698899 0.71 OPRD1 (0.38) P4HBSLC6A4TDO2KCNH2
SCHEMBL13604964 0.70 MAPK1 (0.43) MPOSLC6A4KCNH2DRD2DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1851199-B1 SUBSTITUTED BIS ARYL AND HETEROARYL COMPOUNDS AS SELECTIVE 5HT2A ANTAGONISTS AVENTIS PHARMA INC (US) 2012-05-16 — — EP claimed
US-20070265309-A1 SUBSTITUTED BIS ARYL AND HETEROARYL COMPOUNDS AS SELECTIVE 5HT2A ANTAGONISTS AVENTIS PHARMACEUTICALS INC. (US) 2007-11-15 — — US claimed
EP-1851199-B1 SUBSTITUTED BIS ARYL AND HETEROARYL COMPOUNDS AS SELECTIVE 5HT2A ANTAGONISTS AVENTIS PHARMA INC (US) 2012-05-16 — — EP disclosed
US-7625889-B2 Substituted bis aryl and heteroaryl compounds as selective 5HT2A antagonists AVENTIS PHARMACEUTICALS INC. (US) 2009-12-01 — — US disclosed
US-7618650-B2 Combination of a hypnotic agent and substituted bis aryl and heteroaryl compound and therapeutic application thereof AVENTIS PHARMACEUTICALS INC (US) 2009-11-17 — — US disclosed
US-20080138413-A1 COMBINATION OF A HYPNOTIC AGENT AND SUBSTITUTED BIS ARYL AND HETEROARYL COMPOUND AND THERAPEUTIC APPLICATION THEREOF AVENTIS PHARMACEUTICALS INC. (US) 2008-06-12 — — US disclosed
US-20070265309-A1 SUBSTITUTED BIS ARYL AND HETEROARYL COMPOUNDS AS SELECTIVE 5HT2A ANTAGONISTS AVENTIS PHARMACEUTICALS INC. (US) 2007-11-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080138413-A1 COMBINATION OF A HYPNOTIC AGENT AND SUBSTITUTED BIS ARYL AND HETEROARYL COMPOUND AND THERAPEUTIC APPLICATION THEREOF HCRTR1, HCRTR2, MTNR1B ACHE 1277/4885MPO 1302/4885P4HB 3316/4885
US-20070265309-A1 SUBSTITUTED BIS ARYL AND HETEROARYL COMPOUNDS AS SELECTIVE 5HT2A ANTAGONISTS HTR2A, HTR2B, HTR2C ACHE 2868/4885MPO 2944/4885P4HB 4494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback